Literature DB >> 21890624

Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation.

X Shawn Liu1, Bing Song, Bennett D Elzey, Timothy L Ratliff, Stephen F Konieczny, Liang Cheng, Nihal Ahmad, Xiaoqi Liu.   

Abstract

Loss of the tumor suppressor Pten (phosphatase and tensin homolog deleted on chromosome 10) is thought to mediate the majority of prostate cancers, but the molecular mechanism remains elusive. In this study, we demonstrate that Pten-depleted cells suffer from mitotic stress and that nuclear function of Pten, but not its phosphatase activity, is required to reverse this stress phenotype. Further, depletion of Pten results in elevated expression of Polo-like kinase 1 (Plk1), a critical regulator of the cell cycle. We show that overexpression of Plk1 correlates with genetic inactivation of Pten during prostate neoplasia formation. Significantly, we find that elevated Plk1 is critical for Pten-depleted cells to adapt to mitotic stress for survival and that reintroduction of wild-type Pten into Pten-null prostate cancer cells reduces the survival dependence on Plk1. We further show that Plk1 confers the tumorigenic competence of Pten-deleted prostate cancer cells in a mouse xenograft model. These findings identify a role of Plk1 in facilitating loss of Pten-induced prostate cancer formation, which suggests that Plk1 might be a promising target for prostate cancer patients with inactivating Pten mutations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21890624      PMCID: PMC3195584          DOI: 10.1074/jbc.C111.269050

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).

Authors:  Patrick Schöffski; Jean-Yves Blay; Jacques De Greve; Etienne Brain; Jean-Pascal Machiels; Jean-Charles Soria; Stefan Sleijfer; Pascal Wolter; Isabelle Ray-Coquard; Christel Fontaine; Gerd Munzert; Holger Fritsch; Gertraud Hanft; Claire Aerts; Jérome Rapion; Anouk Allgeier; Jan Bogaerts; Denis Lacombe
Journal:  Eur J Cancer       Date:  2010-05-13       Impact factor: 9.162

Review 2.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

3.  An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.

Authors:  Ralf-Dieter Hofheinz; Salah-Eddin Al-Batran; Andreas Hochhaus; Elke Jäger; Volker L Reichardt; Holger Fritsch; Dirk Trommeshauser; Gerd Munzert
Journal:  Clin Cancer Res       Date:  2010-08-03       Impact factor: 12.531

4.  Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery.

Authors:  X Shawn Liu; Hongchang Li; Bing Song; Xiaoqi Liu
Journal:  EMBO Rep       Date:  2010-06-25       Impact factor: 8.807

5.  Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner.

Authors:  Min Sup Song; Arkaitz Carracedo; Leonardo Salmena; Su Jung Song; Ainara Egia; Marcos Malumbres; Pier Paolo Pandolfi
Journal:  Cell       Date:  2011-01-21       Impact factor: 41.582

6.  Tenets of PTEN tumor suppression.

Authors:  Leonardo Salmena; Arkaitz Carracedo; Pier Paolo Pandolfi
Journal:  Cell       Date:  2008-05-02       Impact factor: 41.582

7.  Pten in stromal fibroblasts suppresses mammary epithelial tumours.

Authors:  Anthony J Trimboli; Carmen Z Cantemir-Stone; Fu Li; Julie A Wallace; Anand Merchant; Nicholas Creasap; John C Thompson; Enrico Caserta; Hui Wang; Jean-Leon Chong; Shan Naidu; Guo Wei; Sudarshana M Sharma; Julie A Stephens; Soledad A Fernandez; Metin N Gurcan; Michael B Weinstein; Sanford H Barsky; Lisa Yee; Thomas J Rosol; Paul C Stromberg; Michael L Robinson; Francois Pepin; Michael Hallett; Morag Park; Michael C Ostrowski; Gustavo Leone
Journal:  Nature       Date:  2009-10-22       Impact factor: 49.962

8.  Principles of cancer therapy: oncogene and non-oncogene addiction.

Authors:  Ji Luo; Nicole L Solimini; Stephen J Elledge
Journal:  Cell       Date:  2009-03-06       Impact factor: 41.582

9.  A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer.

Authors:  Antonio Jimeno; Belen Rubio-Viqueira; N V Rajeshkumar; Audrey Chan; Anna Solomon; Manuel Hidalgo
Journal:  Mol Cancer Ther       Date:  2010-01-26       Impact factor: 6.261

Review 10.  PTEN, more than the AKT pathway.

Authors:  Carmen Blanco-Aparicio; Oliver Renner; Juan F M Leal; Amancio Carnero
Journal:  Carcinogenesis       Date:  2007-03-06       Impact factor: 4.944

View more
  31 in total

1.  PTEN regulates PLK1 and controls chromosomal stability during cell division.

Authors:  Zhong Zhang; Sheng-Qi Hou; Jinxue He; Tingting Gu; Yuxin Yin; Wen H Shen
Journal:  Cell Cycle       Date:  2016-07-11       Impact factor: 4.534

Review 2.  Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.

Authors:  Christopher J Logothetis; Gary E Gallick; Sankar N Maity; Jeri Kim; Ana Aparicio; Eleni Efstathiou; Sue-Hwa Lin
Journal:  Cancer Discov       Date:  2013-06-28       Impact factor: 39.397

Review 3.  Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.

Authors:  Jijing Luo; Xiaoqi Liu
Journal:  Protein Cell       Date:  2012-03-23       Impact factor: 14.870

Review 4.  The functions and regulation of the PTEN tumour suppressor.

Authors:  Min Sup Song; Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

5.  Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.

Authors:  Zhe Zhang; Xianzeng Hou; Chen Shao; Junjie Li; Ji-Xin Cheng; Shihuan Kuang; Nihal Ahmad; Timothy Ratliff; Xiaoqi Liu
Journal:  Cancer Res       Date:  2014-09-24       Impact factor: 12.701

6.  Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness.

Authors:  Shuhua Yue; Junjie Li; Seung-Young Lee; Hyeon Jeong Lee; Tian Shao; Bing Song; Liang Cheng; Timothy A Masterson; Xiaoqi Liu; Timothy L Ratliff; Ji-Xin Cheng
Journal:  Cell Metab       Date:  2014-03-04       Impact factor: 27.287

7.  PTEN as a Guardian of the Genome: Pathways and Targets.

Authors:  Xinyi Fan; Jeffrey Kraynak; Jonathan P S Knisely; Silvia C Formenti; Wen H Shen
Journal:  Cold Spring Harb Perspect Med       Date:  2020-09-01       Impact factor: 6.915

8.  Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer.

Authors:  Zhe Zhang; Long Chen; Hexiang Wang; Nihal Ahmad; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

9.  Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.

Authors:  Anita T Tandle; Tamalee Kramp; Whoon J Kil; Aditya Halthore; Kristen Gehlhaus; Uma Shankavaram; Philip J Tofilon; Natasha J Caplen; Kevin Camphausen
Journal:  Eur J Cancer       Date:  2013-06-18       Impact factor: 9.162

Review 10.  Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.

Authors:  Ion Cristóbal; Federico Rojo; Juan Madoz-Gúrpide; Jesús García-Foncillas
Journal:  Mol Cell Biol       Date:  2016-05-31       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.